# Moderna and Merck's mRNA Vaccine Prevents Melanoma Recurrence Experimental vaccine shown to prevent return and spread of cancer in high-risk melanoma patients. - **Source:** [NYT > Science](https://brifing.si/source/794f9fbd-c10f-44d6-932d-9039af67922c) - **Published:** 2026-08-19 - **Topic:** [Business](https://brifing.si/c/business) - **Original article:** - **On Brifing:** https://brifing.si/s/d5855435-1921-4d17-86f6-b97b9445fac3 ## Role of mRNA Technology in Cancer Moderna and Merck have developed an experimental mRNA vaccine that prevents melanoma recurrence. Clinical trials showed the vaccine stopped cancer from returning and spreading in high-risk patients. This marks mRNA's first major success beyond COVID-19. The vaccine activates the immune system against tumor cells. ## Clinical Trial Results Research demonstrated the vaccine significantly reduced melanoma recurrence rates. Patients receiving the vaccine showed 44% lower risk of cancer returning. These results highlight mRNA's potential in cancer treatment. The study followed 157 patients for one year. ## Moderna-Merck Collaboration The companies have partnered since 2016 to develop mRNA-based cancer vaccines. Moderna's mRNA tech combines with Merck's immunotherapy expertise. This collaboration advanced personalized cancer vaccines. The project is under FDA's 'Fast Track' program. ## Future of mRNA Vaccines COVID-19 proved mRNA vaccine efficacy. Now the same technology tackles complex diseases like cancer. Experts believe mRNA could revolutionize personalized treatments. The melanoma vaccine stands out as an early promising result. ## Melanoma Treatment Challenges Melanoma ranks among the most aggressive skin cancers. Without early detection, it has high recurrence rates. Traditional treatments fail to prevent recurrence in ~50% of patients. The mRNA vaccine could offer new hope. ## Personalized Vaccine Approach The vaccine targets mutations unique to each patient's tumor. This personalized approach enhances immune response. Moderna developed a protocol targeting 34 mutations per patient. The method promises higher efficacy than standard treatments. ## Economic and Sectoral Impact Successful mRNA cancer vaccines could create a multi-billion dollar market. Analysts predict personalized cancer treatments will exceed $10B by 2027. Moderna and Merck lead this space. Commercialization may spur new biotech investments. ## New Era in Cancer Treatment mRNA technology holds groundbreaking potential for cancer therapy. The melanoma vaccine's success may inspire similar approaches for other cancers. This innovation marks a new chapter in immunotherapy. Results signal a promising phase in cancer fight. ## Sources covering this story - https://www.nytimes.com/2026/08/19/science/moderna-merck-mrna-vaccine-melanoma.html — --- _Summary written by Brifing from the original reporting. Copyright in the original article belongs to its publisher; read the full piece at the link above._